VC
CATX icon

Vestor Capital’s Perspective Therapeutics CATX Stock Holding History

Vestor Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55K Sell
56
-1,098,635
-100% -$4.15M ﹤0.01% 251
2026
Q1 		$4.58M Buy
1,098,691
+1,098,189
+218,763% +$4.64M 0.33% 64
2025
Q4 		$2.67M Sell
502
-971,474
-100% -$2.77M 0.18% 60
2025
Q3 		$3.33M Buy
971,976
+970,875
+88,181% +$3.54M 0.21% 69
2025
Q2 		$119K Sell
1,101
-973,619
-100% -$2.57M 0.01% 179
2025
Q1 		$2.08M Buy
+974,720
New +$2.93M 0.17% 76

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Vestor Capital's CATX Position: Q2 2026 in Review

Vestor Capital reduced its Perspective Therapeutics (CATX) stake by 100% in Q2 2026, selling an estimated $4.15M and leaving 56 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #251.

Vestor Capital first reported a position in CATX in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.58M in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Vestor Capital held 56 shares of Perspective Therapeutics worth $55K as of Q2 2026.
  • Vestor Capital sold 1,098,635 Perspective Therapeutics shares in Q2 2026, an estimated $4.15M.
  • Perspective Therapeutics made up ﹤0.01% of Vestor Capital's portfolio in Q2 2026, its #251 holding.
  • Vestor Capital first reported a position in Perspective Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Vestor Capital's Perspective Therapeutics position peaked at $4.58M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Vestor Capital's 13F filing for Q2 2026, filed 28 Jul 2026.